Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).
Serruys
P W
PW
Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands. p.w.j.c.serruys@erasmusmc.nl
Lemos
P A
PA
van Hout
B A
BA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023903:Coronary Restenosis / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004343:Drug Implants; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000191:economics; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage* / Q000191:economics; D015607:Stents / Q000191:economics; D016019:Survival Analysis; D016896:Treatment Outcome
D004343:Drug Implants; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D020123:Sirolimus